MétaCan
Menu
Back to cohort

4CPS-097 Secondline treatment of metastatic non-small cell lung cancer with immune checkpoint inhibitors

2020· article· en· W3016962124 on OpenAlexfundno aff
FJ Salmeron Navas, C Martinez-Diaz, EM Barreiro-Fernandez, Mireia Cantero, S Fénix-Caballero

Bibliographic record

VenueSection 4: Clinical pharmacy services · 2020
Typearticle
Languageen
FieldMedicine
TopicBrain Metastases and Treatment
Canadian institutionsnot available
FundersRio Tinto
KeywordsMedicinePembrolizumabInternal medicineOncologyLung cancerNivolumabAtezolizumabChemotherapyPerformance statusRetrospective cohort studyCancerAdverse effectImmunotherapy

Abstract

fetched live from OpenAlex

Background and importance The therapeutic option in patients with metastatic non-small cell lung cancer (mNSCLC) after chemotherapy is based on the immune checkpoint inhibitors (ICI). Aim and objectives The aim of this study was to analyse the effectiveness, safety and degree of compliance with criteria established in our hospital for patients with mNSCLC undergoing secondline treatment with immunotherapy. Material and methods A retrospective descriptive study including patients with mNSCLC, receiving treatment with atezolizumab, nivolumab or pembrolizumab, from 1 December 2013 to 2 October 2019 was conducted. The electronic prescription programme in oncology and medical records were consulted. Data collected for each patient were sex, age, smoking status, performance status (PS), histology, actives brain metastases, EGFR/ALK/ROS-1 mutations, PDL-1 expression, therapeutic scheme and number of cycles received. Effectiveness was assessed in terms of progression free survival (PFS) and overall survival (OS), calculated by the Kaplan–Meier method. Adverse reactions (AR) of grade ≥3 were collected for analysis of safety. The conditions of use established were: PS=0–1 and patients without active brain metastases or EGFR/ALK/ROS-1 mutations. Results Forty patients, 85% men, were included, with an average age of 70 (42–83) years, of whom 14 were current smokers and 23 were former smokers. A total of 37 patients presented at the beginning of treatment with PS ≤1. There were 18 lung adenocarcinomas and 22 with a non-squamous histology. No patient had active brain metastases at baseline or EGFR/ALK/ROS-1 mutations. PDL-1 expression was ≥1 in 17 patients. The schemes, average numbers and range of cycles were: atezolizumab 1200 mg every 3 weeks, 5 (1–14) cycles; nivolumab 3 mg/kg every 2 weeks, 12 (1–44) cycles; and pembrolizumab 2 mg/kg every 3 weeks, 6 (4–17) cycles. Median PFS and OS were 5 months (95% CI 2.9–7.1) and 14 months (95% CI 8.3–19.7), respectively. AR grade ≥3 reports were: asthenia (29%), pneumonitis (29%), renal disorder (14%), hyperglycaemia (14%) and gastrointestinal symptoms (14%). A total of 7.5% of patients did not comply with the conditions of use established at the start of treatment (PS ≥2). Conclusion and relevance ICI demonstrated a clinical benefit in terms of PFS and OS. The most frequent grade ≥3 AR were asthenia and pneumonitis. Our study suggested a high percentage of compliance with the criteria established. References and/or acknowledgements No conflict of interest.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Other · Consensus signal: none
Teacher disagreement score0.014
Threshold uncertainty score0.047

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.003
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0140.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.057
GPT teacher head0.382
Teacher spread0.325 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueSection 4: Clinical pharmacy servicesSame topicBrain Metastases and TreatmentFrench-language works237,207